Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.
As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...
Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.
President Trump launched TrumpRx, a new initiative aiming to slash prescription drug costs by forging direct deals with ...
18hon MSN
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...
Scripps News on MSN
Eli Lilly seeks FDA approval for pill that maintains weight loss after Wegovy, Zepbound
Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping Wegovy or Zepbound injections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results